Secondary Logo

Complement-mediated Damage to the Glycocalyx Plays a Role in Renal Ischemia-reperfusion Injury in Mice

Bongoni, Anjan K., PhD1; Lu, Bo, PhD1; McRae, Jennifer L., PhD1; Salvaris, Evelyn J., BSc (Hons)1; Toonen, Erik J. M., PhD2; Vikstrom, Ingela, PhD3; Baz Morelli, Adriana, PhD3; Pearse, Martin J., PhD3; Cowan, Peter J., PhD1,4

doi: 10.1097/TXD.0000000000000881
Basic Science

Background Complement activation plays an important role in the pathogenesis of renal ischemia-reperfusion (IR) injury (IRI), but whether this involves damage to the vasculoprotective endothelial glycocalyx is not clear. We investigated the impact of complement activation on glycocalyx integrity and renal dysfunction in a mouse model of renal IRI.

Methods Right nephrectomized male C57BL/6 mice were subjected to 22 minutes left renal ischemia and sacrificed 24 hours after reperfusion to analyze renal function, complement activation, glycocalyx damage, endothelial cell activation, inflammation, and infiltration of neutrophils and macrophages.

Results Ischemia-reperfusion induced severe renal injury, manifested by significantly increased serum creatinine and urea, complement activation and deposition, loss of glycocalyx, endothelial activation, inflammation, and innate cell infiltration. Treatment with the anti-C5 antibody BB5.1 protected against IRI as indicated by significantly lower serum creatinine (P = 0.04) and urea (P = 0.003), tissue C3b/c and C9 deposition (both P = 0.004), plasma C3b (P = 0.001) and C5a (P = 0.006), endothelial vascular cell adhesion molecule-1 expression (P = 0.003), glycocalyx shedding (tissue heparan sulfate [P = 0.001], plasma syndecan-1 [P = 0.007], and hyaluronan [P = 0.02]), inflammation (high mobility group box-1 [P = 0.0003]), and tissue neutrophil (P = 0.0009) and macrophage (P = 0.004) infiltration.

Conclusions Together, our data confirm that the terminal pathway of complement activation plays a key role in renal IRI and demonstrate that the mechanism of injury involves shedding of the glycocalyx.

1 Immunology Research Centre, St. Vincent's Hospital, Melbourne, Australia.

2 R&D Department, Hycult Biotech, Uden, The Netherlands.

3 Research and Development, CSL Limited, Parkville, Australia.

4 Department of Medicine, the University of Melbourne, Melbourne, Australia.

Published online 25 March, 2019.

Received 23 January 2019.

Accepted 5 February 2019.

This work was supported in part by National Health & Medical Research Council (NHMRC)–European Union Collaborative research grant 1074171, and by funding from CSL Ltd, Parkville, Australia.

Disclosure: E.J.M.T. is an employee of Hycult Biotech. I.V., A.B., and M.J.P. are employees of CSL Ltd.

A.K.B. participated in the concept and design of the study, performance of experiments, analyzing the data, and writing the article. B.L., J.L.M., E.J.S., and E.J.M.T. participated in performance of the research and data analysis. I.V., A.B., and M.J.P. participated in the research design. P.J.C. participated in the concept and design of the study, performance of experiments, analyzing the data, and writing the article and carried the main responsibility for the study.

Correspondence: Peter J. Cowan, PhD, Immunology Research Centre, St. Vincent's Hospital Melbourne, PO Box 2900, Fitzroy 3065, Victoria, Australia. (

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Compendium date: April, 2019

Ischemia-reperfusion (IR) injury (IRI) is an unavoidable episode in numerous clinical settings, including ischemic acute kidney injury, myocardial infarction, and stroke, and has systemic manifestations that contribute to multiorgan failure.1 In transplantation, IRI can have profound detrimental effects on short- and long-term graft functions. The mechanisms involved in IRI are complex and incompletely understood. A number of factors contribute to the pathogenesis of IRI, in which local upregulation and activation of the complement cascade, an arm of the innate immune system, play a key role.2

The complement cascade has 3 initiating pathways (classical, lectin, and alternative) that converge to activate a common terminal pathway that results in the formation of the C5b-9 membrane attack complex (MAC). The anaphylatoxins C3a and C5a mediate activation of inflammation by inducing cytokine production, immune and endothelial cell activation, adhesion molecule (eg, vascular cell adhesion molecule-1 [VCAM-1]) upregulation, and increased vascular permeability.3 The MAC mediates innate cell infiltration and proinflammatory cytokine production and directly causes cell activation or lysis.4,5 Thus, complement-related tissue injury may be induced by the terminal complement complex C5b-9, by cell-bound ligands, including C4b and C3b, and by circulating C3a and C5a.

Endothelial cell activation, also known to be involved in IRI, is characterized by shedding of the glycocalyx and increased expression of adhesion molecules and release of damage-associated molecular patterns (such as heparan sulfate [HS], heat shock proteins, and high mobility group box-1 [HMGB1]), with consequent activation of the plasma cascade systems.6 The endothelial glycocalyx is a negatively charged mesh-like hydrated structure covering the luminal surface of endothelial cells. Proteoglycans like syndecans 1 and 4 and glypican 1, with bound glycosaminoglycans, of which HS and hyaluronan constitute up to 90%,7-9 are the main contributors to glycocalyx structure and function. This carbohydrate-rich layer with its associated proteins mediates many of the regulatory functions of the endothelium,10 and the endothelial glycocalyx acts as the epicenter of the pathophysiology of various cardiovascular and renal diseases.11 The IRI-induced shedding of the glycocalyx has been demonstrated in trauma patients12 and dialysis patients,13 rat cardiac IRI,14 guinea pig cardiac IRI,15 and vascular inflammation in rats.16 Rehm et al17 reported elevated plasma concentrations of syndecan-1 and HS as soluble markers of the damaged glycocalyx in patients after cardiac ischemia on cardiopulmonary bypass. This evidence shows that alteration of the glycocalyx is widely involved in endothelial damage caused by inflammation, and therapeutic strategies aiming at preserving its integrity may improve the outcome of IRI-related diseases.

Both anaphylatoxin (C3a, C5a)- and MAC-dependent mechanisms have been implicated in renal IRI.18-21 De Vries et al22,23 demonstrated both neutrophil-dependent and -independent effects of C5a in the pathogenesis of renal IRI. The MAC mediates neutrophil influx and inflammation, in addition to directly causing cellular damage and death.19 Attempts to inhibit complement in IRI have targeted the classical and lectin pathways (C1 esterase inhibitor [C1-INH], C1s antagonist/antibodies), the lectin pathway alone (anti-MBL antibodies), or all 3 pathways (soluble complement receptor 1, anti-C5/C5a, C5a receptor antagonists).2,24,25 C5 inhibition protects against IRI of the brain,26 lung,27 and myocardium28 and renal23 and allograft vasculopathy.29 However, the effect of C5 blockade during renal IRI on shedding of the endothelial glycocalyx has not been investigated. In this study, we hypothesized that efficient inhibition of complement activation would attenuate renal IRI at least in part by preserving glycocalyx integrity. We tested this hypothesis in a mouse model of renal IRI by investigating whether (1) renal dysfunction is associated with complement activation and shedding of the endothelial glycocalyx, and (2) inhibition of complement using an antimouse C5 antibody would reduce glycocalyx damage and preserve renal function.

Back to Top | Article Outline



Ten- to 12-week-old male C57BL/6 wild type mice were purchased from the Animal Resources Centre (Canning Vale, Western Australia). Mice were housed in an approved animal facility (Bioresources Centre, St. Vincent's Hospital Melbourne), and all experiments were approved by the Animal Ethics Committee of St. Vincent's Hospital Melbourne.

Back to Top | Article Outline

Warm Renal IRI

Mice were anesthetized by intraperitoneal administration of ketamine and xylazine and their core body temperature was maintained at 37°C during surgery by placing the mice on a heating pad. The kidneys were exposed by a midline abdominal incision and the renal pedicles were bluntly dissected. After right nephrectomy, ischemia was induced by occlusion of the left renal pedicle with a microvascular clamp (Roboz, Rockville, MD) for 22 minutes at 37°C in a temperature-controlled chamber. The clamp was removed after 22 minutes and the kidney was observed to confirm complete reperfusion. Sham-operated mice had right nephrectomy only without IR. All mice received 100 mL/kg of warm saline into the abdominal cavity during the procedure. The mice were recovered on a heat pad at 37°C. 24 hours after reperfusion, the mice were sacrificed by exsanguination, and blood and kidney samples were obtained.

Experimental groups (n = 7–8 per group) were as follows: (1) IRI mice treated with anti-C5 monoclonal antibody (mAb) BB5.1 (IRI/BB5.1), (2) IRI mice treated with isotype control antibody (IRI/isotype), and (3) sham control (Sham). 80 mg/kg (200–220 μL volume) of mouse antimurine C5 clone BB5.1 (a kind gift of Dr John Lambris, University of Pennsylvania, Philadelphia, PA) or isotype control mAb (BM4, mouse IgG1κ; CSL Ltd, Parkville, Australia) was administered intravenously just before ischemia. The sham mice did not receive any treatment.

Back to Top | Article Outline

Assessment of Renal Function

Renal function was assessed by measuring serum creatinine using a kinetic colorimetric assay based on the Jaffé method and analyzed on a COBAS Integra 400 Plus analyzer (Roche, Castle Hill, Australia) in accordance with the manufacturer's instructions. Serum urea was measured using Urea Assay Kit STA-382 (Cell Biolabs, San Diego, CA) as per the manufacturer's instructions.

Back to Top | Article Outline

Enzyme-linked Immunosorbent Assay for Complement C3b and C5a, Hyaluronan, Syndecan-1, and HMGB1

Plasma samples were analyzed using commercial ELISA kits for mouse C3b (HK216, Hycult Biotech, Uden, The Netherlands), C5a (DY2150; R&D Systems, Minneapolis, MN), hyaluronan (DY3614; R&D Systems), and syndecan-1 (75-138MS-S10; Alpco, Salem, NH), as per the manufacturer's instructions.

Plasma HMGB1 was measured using an in-house ELISA. In brief, a capture antibody, rabbit anti-HMGB1 (H9539; Sigma-Aldrich, Castle Hill, Australia) and detection antibody, HRP-conjugated rabbit anti-HMGB1 (ab128129; Abcam, Melbourne, Australia) were used, followed by SureBlue TMB Microwell Peroxidase Substrate (KPL 52-00-01, SeraCare, Milford, MA). Human HMGB1 full length protein, which shares 99% sequence homology with mouse HMGB1, was used as standard. Optical density was measured at 450/540 nm using a FLUOstar Omega microplate reader (BMG Labtech GmbH, Offenburg, Germany).

Back to Top | Article Outline


Fresh-frozen tissue sections (5 μm) were fixed with acetone and incubated with rabbit anti-C3b/c FITC (Dako), rabbit anti-C9 Alexa 488 (Bioss Antibodies, Woburn, MA), mouse anti-HS FITC (10E4 epitope, H1890; US Biologicals, Salem MA), rat antimouse VCAM-1 Alexa 488 (MCA2297; Bio-Rad, Raleigh, NC), rat antimouse Ly-6G FITC (Hycult Biotech), or rat antimouse F4/80 FITC (AbD Serotec). The slides were analyzed using a confocal microscope (Nikon A1R). Quantification of fluorescence intensity as raw integrated density ([RawIntDen], for C3b/c, C9, and HS with staining throughout the tissue) and mean gray values (for VCAM-1 with staining specifically in blood vessels) was performed using Image J software version 10.2 (National Institutes of Health).

Back to Top | Article Outline

Statistical Analysis

Results are presented as means ± standard error of the mean (SEM). Data plotting and statistical analysis were performed using Prism version 5.0 (GraphPad). Differences between the 2 groups were statistically evaluated using nonparametric t-test with Mann-Whitney U test (2-tailed) and a P value of <0.05 was considered to be statistically significant.

Back to Top | Article Outline


Treatment With Anti-C5 mAb BB5.1 Protects Against IR-induced Renal Injury

In mice subjected to right nephrectomy and 22 minutes left renal ischemia, severe loss of renal function was evident 24 hours after reperfusion. Serum creatinine (IRI/isotype group 190.0 ± 25.0 μmol/L vs sham 31.2 ± 1.7 μmol/L, P = 0.002) and urea (IRI/isotype 437.4 ± 12.2 mg/dL vs sham 73.8 ± 7.1 mg/dL, P = 0.0006) were both significantly elevated (Figure 1A and B). Treatment with the anti-C5 mAb BB5.1 just before ischemia (IRI/BB5.1 group) significantly reduced renal injury as seen by lower serum creatinine (121.0 ± 9.8 μmol/L, P = 0.04) and urea (316.3 ± 22.9 mg/dL, P = 0.003) compared with the IRI/isotype group, indicating that BB5.1 was protective against renal IRI in this model (Figure 1A and B).



Back to Top | Article Outline

Inhibition of C5 Activation by BB5.1 Treatment Reduces IR-induced Complement Activation and MAC Formation

Next, we investigated the effect of BB5.1 on complement activation during renal IRI. The degree of complement activation was measured using 2 methods: tissue deposition of C3b/c and C9 (as a measure of the MAC) and analysis of systemic C3b and C5a levels. Immunofluorescence/confocal analysis of kidney sections from sham-operated mice exhibited minimal C3b/c (Figure 2A) and C9 (Figure 2C). Sections from IRI/isotype mice showed significant deposition of C3b/c on the basement membrane of tubular and glomerular epithelium and vascular endothelium (Figure 2A) and of C9 on the basement membrane of tubular epithelium and vascular endothelium (Figure 2C). Deposition of C3b/c (P = 0.004) and C9 (P = 0.004) was significantly reduced in IRI/BB5.1 mice compared with IRI/isotype mice (Figure 2A–D). These results indicate the involvement of C3 and the terminal pathway of complement (C5b-9) in renal IRI.



We next determined systemic complement activation products by measuring plasma C3b and C5a. The C3b and C5a levels in IRI/isotype mice were significantly increased 24 hours after reperfusion (C3b: 4913.0 ± 460.1 AU/mL vs sham 455.0 ± 81.5 AU/mL, P = 0.0002; C5a: 22.7 ± 2.0 ng/mL vs sham 3.4 ± 0.7 ng/mL, P = 0.001) (Figure 3A and B). Consistent with its effects on complement tissue deposition, BB5.1 treatment significantly decreased plasma C3b (2559.0 ± 340.1 AU/mL, P = 0.001) and C5a (14.0 ± 1.5 ng/mL, P = 0.006) levels compared with the IRI/isotype group (Figure 3A and B).



Back to Top | Article Outline

Blockade of MAC Assembly by BB5.1 Attenuates IR-induced Endothelial Activation and Inflammation

Alterations in renal endothelial function contribute to a reduction in renal blood flow and also influence vasodilation, coagulation, and inflammation following IR (reviewed in Basile and Yoder30). Therefore, we investigated the activation of the renal endothelium by assessing expression of the adhesion molecule VCAM-1 by immunofluorescence staining and confocal analysis. Expression of VCAM-1 was significantly upregulated (P = 0.0006) in the IRI/isotype group compared with sham-operated mice (Figure 4A and B) and correlated well with complement activation and deposition (with tissue C3b/c: r 2 = 0.86, P = 0.003; tissue C9: r 2 = 0.9, P = 0.001; data not shown). In contrast, expression of VCAM-1 was significantly reduced (P = 0.003) in samples from IRI/BB5.1 mice compared with IRI/isotype mice (Figure 4A and B) and correlated well with complement deposition after BB5.1 treatment (with tissue C3b/c: r 2 = 0.77, P = 0.01; tissue C9: r 2 = 0.78, P = 0.009; data not shown). Taken together, these data indicated that the inhibition of complement by BB5.1 reduced endothelial activation and preserved endothelial integrity.



Plasma HMGB1 levels, measured as important mediators of cellular activation and inflammation, were significantly increased after IR in the isotype-treated mice (31.3 ± 1.7 ng/mL vs sham 6.4 ± 0.9 ng/mL, P = 0.0006) (Figure 4C). BB5.1 treatment resulted in a significant reduction in plasma HMGB1 (14.8 ± 2.0 ng/mL, P = 0.0003 vs IRI/isotype) (Figure 4C).

Back to Top | Article Outline

Terminal Complement Inhibition by BB5.1 Prevents IR-induced Glycocalyx Damage

To evaluate the role of complement and renal IRI in the glycocalyx damage, expressions of vascular HS, syndecan-1 and hyaluronan and tubular syndecan-1 and hyaluronan were measured by immunofluorescence and confocal staining. In the kidney of sham-operated mice, HS, syndecan-1, and hyaluronan were abundantly present on glomerular basement membrane and interstitium, tubular basement membrane, renal arterioles, the sub-intimal region, adventitia, and around smooth muscle cells of the media (Figure 5A). In contrast, vascular expression of HS, syndecan-1, and hyaluronan were greatly reduced, with a dramatic loss of staining intensity in kidneys from IRI/isotype mice (Figure 5A). Treatment with BB5.1 reduced this IR-induced loss of vascular HS, syndecan-1, and hyaluronan (Figure 5A). Interestingly, tubular accumulation of syndecan-1 and hylauronan was observed in the cortex and outer medulla in kidneys from IRI/isotype mice, possibly representing glycocalyx shed from the corticomedullary region of the kidney. This accumulation was reduced in BB5.1-treated mice (Figure 5A).



Since increased plasma syndecan-1 and hyaluronan levels are associated with glycocalyx breakdown, and they reflect different components of the glycocalyx (syndecan-1 as a core glycoprotein and hyaluronan as a loosely attached substance), we chose them as markers of the endothelial glycocalyx damage. Plasma levels of both markers were increased in IRI/isotype mice compared with sham-operated mice (syndecan-1 4510.0 ± 661.2 pg/mL vs sham: 349.0 ± 93.1 pg/mL, P = 0.001; hyaluronan 6658.0 ± 829.6 ng/mL vs sham: 1888.0 ± 414.5 ng/mL, P = 0.003) (Figure 5B). Treatment with BB5.1 significantly reduced circulating syndecan-1 (1393.0 ± 427.1 pg/mL, P = 0.007) and hyaluronan (3745.0 ± 553.2 pg/mL, P = 0.02) levels compared with isotype-treated mice (Figure 5B).

Back to Top | Article Outline

BB5.1 Treatment Reduces IR-induced Innate Cell Tissue Infiltration

To further characterize local renal inflammation upon IR, infiltrating Ly-6G-positive neutrophils and F4/80-positive macrophages were quantified by immunofluorescence and confocal staining. No or very few (1 or 2 cells per high-power field [HPF]) infiltrating neutrophils and macrophages were found in sham-operated kidneys (Figure 6A–D). Renal IRI induced significant recruitment of neutrophils (IRI/isotype 59.0 ± 3.0 cells/HPF vs sham, P = 0.0008) (Figure 6A and B) and macrophages (63.0 ± 5.0 cells/HPF vs sham, P = 0.0009) (Figure 6C and D) within the tubular interstitium at the corticomedullary junction corresponding to the area of severe injury and complement deposition. Kidneys from the IRI/BB5.1 group showed a significant reduction in infiltration of neutrophils (24.0 ± 4.0 cells/HPF, P = 0.0009) (Figure 6A and B) and macrophages (29.0 ± 7.0 cells/HPF, P = 0.004) (Figure 6C and D) compared with kidneys from the IRI/isotype group.



Back to Top | Article Outline


Acute ischemic injury of kidneys transplanted from donors after circulatory death is characterized by loss of integrity of the endothelial glycocalyx compared with kidneys from living donors.31 The proposed mechanisms of glycocalyx shedding/degradation in the inflammatory transplant setting include endothelial cell activation and the action of reactive oxygen species and proteases released by activated neutrophils recruited to the graft.32 Since complement activation contributes to these processes, we evaluated the effect of complement inhibition using an anti-C5 mAb on the loss of glycocalyx and impairment of renal function in a mouse model of renal IRI. C5 blockade prevented destruction of the glycocalyx and preserved kidney function, demonstrating a causal connection between terminal complement activation, glycocalyx damage, and IRI.

Complement activation is an early event in renal IRI and transplantation.21,33 Although the relative involvement of the individual activation pathways remains a subject of debate, recent reports have indicated that local production of complement effector molecules34-36 and the loss or abnormal expression of complement inhibitors37 are possible contributors to complement activation following IRI. Complement activation products, such as C1q, C3a, C5a, and C5b-9, can directly activate and adversely affect endothelial function.38 Upon reperfusion, an important and early reaction of the endothelium is the shedding of its native anticoagulant and anti-inflammatory surface layer, the glycocalyx. In addition, complement-mediated endothelial activation can potentially initiate and subsequently extend the initial tubular injury. This leads to the local release of damage-associated molecular patterns (eg, HMGB1) and other inflammatory mediators (eg, cytokines) and the expression of cell surface molecules to trigger activation of innate immune cells.39,40 Therefore, effective inhibition of complement activation may offer tissue protection after reperfusion.

Reduced renal function following IRI in this study was associated with increased tubular complement C3b/c and C9 deposition and plasma C3b and C5a levels. In addition, we found significantly higher expression of VCAM-1, a marker of endothelial cell activation, and increased levels of circulating HMGB1. Extracellular HMGB1, secreted from necrotic or damaged cells or activated inflammatory cells, initiates potent innate immune responses in the pathogenesis of a range of inflammatory states, including IRI and transplant rejection.41,42 Treatment with BB5.1 protected against IR-induced renal dysfunction, reduced complement activation and deposition, and attenuated endothelial activation and damage, reflected by reduced VCAM-1 expression and HMGB1 release. These results provide convincing evidence that complement activation is a critical effector mechanism that mediates postischemic renal inflammation and injury. Interestingly, blockade of C5 activation with BB5.1 also reduced the activation of C3, which is a preceding component in the complement cascade. We hypothesize that inhibition of the formation of C5a and C5b-9 reduced secondary cellular damage and inflammation including neutrophil recruitment, resulting in a reduction in ongoing C3 activation.

In normal conditions, glycocalyx components such as heparin/HS possess anticomplement properties through binding to various complement inhibitors.43 Unregulated complement activation can induce shedding of this layer to create a proinflammatory and procoagulant endothelial surface, which is crucial for endothelial activation and dysfunction.44,45 Furthermore, the anaphylatoxin C5a activates neutrophils to produce reactive oxygen and nitrogen species and release granular proteases, all of which can cause shedding of the glycocalyx.46,47 Damage to the glycocalyx intensifies IRI in 2 distinct ways: loss of glycocalyx-related physiological functions from the cell surface, resulting in increased leukocyte- and platelet-endothelial interactions, inflammation, oxidative stress, and interstitial edema;48 and release of shed glycocalyx fragments which can amplify the immune response by directly activating leukocytes and endothelial cells.49 We therefore measured the tissue expression of HS, syndecan-1 and hyaluronan (presence of functional glycocalyx), and plasma levels of shed syndecan-1 and hyaluronan (degradation of glycocalyx). Indeed, we found a significant loss of the glycocalyx following IRI, indicated by reduced renal HS expression and elevated plasma syndecan-1 and hyaluronan levels. Treatment with BB5.1 significantly reduced IR-induced tissue HS shedding and plasma syndecan-1 and hyaluronan, indicating preservation of the integrity of the glycocalyx. Together, these data support the notion that complement-mediated renal endothelial injury and dysfunction play a pivotal part in glycocalyx damage and renal dysfunction.

In line with previous reports, our study confirms that IRI can disrupt the integrity of the glycocalyx. Considerable evidence suggests that a variety of enzymes, increased oxidative stress, secondary inflammatory responses, and microvascular endothelial dysfunction contribute directly to the degradation of the glycocalyx (as reviewed in Lipowsky47). Activated inflammatory cells and resident macrophages produce oxygen/nitrogen species that can facilitate increased shedding of the glycocalyx via activation of sheddases and inhibition of endogenous protease inhibitors.10,46,47,49,50 In addition, sustained endothelial activation induces increased release of enzymes such as heparanase and hyaluronidase that degrade the glycocalyx (as reviewed in Rabelink and de Zeeuw51). Matrix metalloproteinases, neutrophil elastase, thrombin, plasmin, tryptase, and cathepsin B, which are proteases released and activated under inflammatory conditions, cause shedding of the glycocalyx.50 A limitation of the current study is that the precise mechanisms of glycocalyx shedding in renal IRI are not fully explored. Previous evidence suggests that the loss of glycocalyx function is reversible upon restoration of endothelial function.52 Our results show that complement inhibition with anti-C5 attenuates endothelial activation and thereby limits glycocalyx destruction. Nevertheless, further experimental and clinical studies on glycocalyx shedding in renal IRI are warranted.

Complement-induced endothelial activation (evidenced by upregulated VCAM-1 expression), inflammation (HMGB1), and loss of glycocalyx might lead to extravasation of leukocytes, including neutrophils and macrophages, through the microvascular endothelium and subsequently further endothelial injury and dysfunction and tubular injury. This is particularly important in the medullary region as endothelial cells in this region express important surface markers for leukocyte activation.53 Activated proximal tubular epithelial cells and leukocytes produce cytokines and chemokines that induce further cell infiltration and inflammation.54 In this study, infiltration of neutrophils and macrophages has been documented in the corticomedullary junction of the kidney. These data provide evidence for the participation of innate cell infiltration and strongly implicate the involvement of C5a and C5b-9 in renal IRI. BB5.1 prevents generation of both C5a and C5b, and thereby C5b-9. Our data also show that inhibition of C5 using BB5.1 significantly reduced the influx of neutrophils as well as macrophages after IR. Together, these data emphasize that activation of C5 is central to the influx of neutrophils and macrophages and its inhibition with BB5.1 may also have contributed to the improved renal function by reducing cellular damage.

In summary, IRI-induced renal dysfunction was strongly associated with complement activation, complement-mediated endothelial glycocalyx damage, and innate immune cell infiltration. Inhibition of C5 significantly attenuated complement C3b/c and C9 deposition, endothelial activation, loss of the glycocalyx, and cellular infiltration. These data suggest an important role for the terminal pathway of complement in the injury process. Therefore, effective complement inhibition, by blocking the terminal pathway of complement, may prevent destruction of the glycocalyx and inflammation, thereby preserving kidney function following renal IRI.

Back to Top | Article Outline


The authors thank staff at the Immunology Research Centre (IRC), St. Vincent's Hospital Melbourne, for technical support and advice, and staff at the Bioresources Centre for animal care.

Back to Top | Article Outline


1. Eltzschig HK, Eckle T. Ischemia and reperfusion—from mechanism to translation. Nat Med. 2011;17:1391–1401.
2. Diepenhorst GM, van Gulik TM, Hack CE. Complement-mediated ischemia-reperfusion injury: lessons learned from animal and clinical studies. Ann Surg. 2009;249:889–899.
3. Ward PA. The harmful role of c5a on innate immunity in sepsis. J Innate Immun. 2010;2:439–445.
4. Walport MJ. Complement. First of two parts. N Engl J Med. 2001;344:1058–1066.
5. Walport MJ. Complement. Second of two parts. N Engl J Med. 2001;344:1140–1144.
6. Bonventre JV, Yang L. Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest. 2011;121:4210–4221.
7. Reitsma S, Slaaf DW, Vink H, et al. The endothelial glycocalyx: composition, functions, and visualization. Pflugers Arch. 2007;454:345–359.
8. Ihrcke NS, Wrenshall LE, Lindman BJ, et al. Role of heparan sulfate in immune system-blood vessel interactions. Immunol Today. 1993;14:500–505.
9. Pries AR, Secomb TW, Gaehtgens P. The endothelial surface layer. Pflugers Arch. 2000;440:653–666.
10. Dane MJ, van den Berg BM, Lee DH, et al. A microscopic view on the renal endothelial glycocalyx. Am J Physiol Ren Physiol. 2015;308:F956–F966.
11. Chelazzi C, Villa G, Mancinelli P, et al. Glycocalyx and sepsis-induced alterations in vascular permeability. Crit Care. 2015;19:26.
12. Rahbar E, Cardenas JC, Baimukanova G, et al. Endothelial glycocalyx shedding and vascular permeability in severely injured trauma patients. J Transl Med. 2015;13:117.
13. Vlahu CA, Lemkes BA, Struijk DG, et al. Damage of the endothelial glycocalyx in dialysis patients. J Am Soc Nephrol. 2012;23:1900–1908.
14. Czarnowska E, Karwatowska-Prokopczuk E. Ultrastructural demonstration of endothelial glycocalyx disruption in the reperfused rat heart. Involvement of oxygen free radicals. Basic Res Cardiol. 1995;90:357–364.
15. Chappell D, Jacob M, Hofmann-Kiefer K, et al. Antithrombin reduces shedding of the endothelial glycocalyx following ischaemia/reperfusion. Cardiovasc Res. 2009;83:388–396.
16. Lipowsky HH, Gao L, Lescanic A. Shedding of the endothelial glycocalyx in arterioles, capillaries, and venules and its effect on capillary hemodynamics during inflammation. Am J Physiol Heart Circ Physiol. 2011;301:H2235–H2245.
17. Rehm M, Bruegger D, Christ F, et al. Shedding of the endothelial glycocalyx in patients undergoing major vascular surgery with global and regional ischemia. Circulation. 2007;116:1896–1906.
18. Peng Q, Li K, Smyth LA, et al. C3a and C5a promote renal ischemia-reperfusion injury. J Am Soc Nephrol. 2012;23:1474–1485.
19. Zhou W, Farrar CA, Abe K, et al. Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest. 2000;105:1363–1371.
20. Yamada K, Miwa T, Liu J, et al. Critical protection from renal ischemia reperfusion injury by CD55 and CD59. J Immunol. 2004;172:3869–3875.
21. Bongoni AK, Lu B, Salvaris EJ, et al. Overexpression of human CD55 and CD59 or treatment with human CD55 protects against renal ischemia-reperfusion injury in mice. J Immunol. 2017;198:4837–4845.
22. de Vries B, Matthijsen RA, Wolfs TG, et al. Inhibition of complement factor C5 protects against renal ischemia-reperfusion injury: inhibition of late apoptosis and inflammation. Transplantation. 2003;75:375–382.
23. de Vries B, Kohl J, Leclercq WK, et al. Complement factor C5a mediates renal ischemia-reperfusion injury independent from neutrophils. J Immunol. 2003;170:3883–3889.
24. Damman J, Schuurs TA, Ploeg RJ, et al. Complement and renal transplantation: from donor to recipient. Transplantation. 2008;85:923–927.
25. Riedemann NC, Ward PA. Complement in ischemia reperfusion injury. Am J Pathol. 2003;162:363–367.
26. Costa C, Zhao L, Shen Y, et al. Role of complement component C5 in cerebral ischemia/reperfusion injury. Brain Res. 2006;1100:142–151.
27. Harkin DW, Marron CD, Rother RP, et al. C5 complement inhibition attenuates shock and acute lung injury in an experimental model of ruptured abdominal aortic aneurysm. Br J Surg. 2005;92:1227–1234.
28. Vakeva AP, Agah A, Rollins SA, et al. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation. 1998;97:2259–2267.
29. Qin L, Li G, Kirkiles-Smith N, et al. Complement C5 inhibition reduces T cell-mediated allograft vasculopathy caused by both alloantibody and ischemia reperfusion injury in humanized mice. Am J Transplant. 2016;16:2865–2876.
30. Basile DP, Yoder MC. Renal endothelial dysfunction in acute kidney ischemia reperfusion injury. Cardiovasc Hematol Disord Drug Targets. 2014;14:3–14.
31. Snoeijs MG, Vink H, Voesten N, et al. Acute ischemic injury to the renal microvasculature in human kidney transplantation. Am J Physiol Ren Physiol. 2010;299:F1134–F1140.
32. Song JW, Goligorsky MS. Perioperative implication of the endothelial glycocalyx. Korean J Anesthesiol. 2018;71:92–102.
33. Casiraghi F, Azzollini N, Todeschini M, et al. Complement alternative pathway deficiency in recipients protects kidney allograft from ischemia/reperfusion injury and alloreactive T cell response. Am J Transplant. 2017;17:2312–2325.
34. Pratt JR, Abe K, Miyazaki M, et al. In situ localization of C3 synthesis in experimental acute renal allograft rejection. Am J Pathol. 2000;157:825–831.
35. Pratt JR, Basheer SA, Sacks SH. Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med. 2002;8:582–587.
36. Farrar CA, Zhou W, Lin T, et al. Local extravascular pool of C3 is a determinant of postischemic acute renal failure. FASEB J. 2006;20:217–226.
37. Thurman JM, Ljubanovic D, Royer PA, et al. Altered renal tubular expression of the complement inhibitor Crry permits complement activation after ischemia/reperfusion. J Clin Invest. 2006;116:357–368.
38. Morgan BP. Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects. Biochem J. 1989;264:1–14.
39. Wu H, Ma J, Wang P, et al. HMGB1 contributes to kidney ischemia reperfusion injury. J Am Soc Nephrol. 2010;21:1878–1890.
40. Li J, Gong Q, Zhong S, et al. Neutralization of the extracellular HMGB1 released by ischaemic damaged renal cells protects against renal ischaemia-reperfusion injury. Nephrol Dial Transplant. 2011;26:469–478.
41. Chen Q, Guan X, Zuo X, et al. The role of high mobility group box 1 (HMGB1) in the pathogenesis of kidney diseases. Acta Pharm Sin B. 2016;6:183–188.
42. Zhu P, Xie L, Ding HS, et al. High mobility group box 1 and kidney diseases (review). Int J Mol Med. 2013;31:763–768.
43. Zaferani A, Talsma D, Richter MK, et al. Heparin/heparan sulphate interactions with complement—a possible target for reduction of renal function loss? Nephrol Dial Transplant. 2014;29:515–522.
44. Bongoni AK, Salvaris E, Nordling S, et al. Surface modification of pig endothelial cells with a branched heparin conjugate improves their compatibility with human blood. Sci Rep. 2017;7:4450.
45. Ihrcke NS, Platt JL. Shedding of heparan sulfate proteoglycan by stimulated endothelial cells: evidence for proteolysis of cell-surface molecules. J Cell Physiol. 1996;168:625–637.
46. van Golen RF, van Gulik TM, Heger M. Mechanistic overview of reactive species-induced degradation of the endothelial glycocalyx during hepatic ischemia/reperfusion injury. Free Radic Biol Med. 2012;52:1382–1402.
47. Lipowsky HH. Protease activity and the role of the endothelial glycocalyx in inflammation. Drug Discov Today Dis Model. 2011;8:57–62.
48. Li L, Bonventre JV. Endothelial glycocalyx: not just a sugar coat. Am J Respir Crit Care Med. 2016;194:390–393.
49. van Golen RF, Reiniers MJ, Vrisekoop N, et al. The mechanisms and physiological relevance of glycocalyx degradation in hepatic ischemia/reperfusion injury. Antioxid Redox Signal. 2014;21:1098–1118.
50. Becker BF, Jacob M, Leipert S, et al. Degradation of the endothelial glycocalyx in clinical settings: searching for the sheddases. Br J Clin Pharmacol. 2015;80:389–402.
51. Rabelink TJ, de Zeeuw D. The glycocalyx–linking albuminuria with renal and cardiovascular disease. Nat Rev Nephrol. 2015;11:667–676.
52. Oltean S, Qiu Y, Ferguson JK, et al. Vascular endothelial growth factor-A165b is protective and restores endothelial glycocalyx in diabetic nephropathy. J Am Soc Nephrol. 2015;26:1889–1904.
53. Kinjo T, Takashi M, Miyake K, et al. Phenotypic heterogeneity of vascular endothelial cells in the human kidney. Cell Tissue Res. 1989;256:27–34.
54. Kelly KJ, Molitoris BA. Acute renal failure in the new millennium: time to consider combination therapy. Semin Nephrol. 2000;20:4–19.
© 2019 The Authors. Published by Wolters Kluwer Health, Inc.